Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Eidos chases Pfizer in amyloidosis
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
Vertex and Crispr up the ante in gene therapy chase
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
12 years on, Astra draws a line under Medimmune
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Esketamine floats past adcom vote
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Glaxo adds flesh to its oncology ambitions
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.